Molgramostim
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
NDAActive
Key Facts
About PARI Pharma
PARI Pharma is a long-established, privately-held German company that has evolved into a leading partner for inhaled drug development, leveraging its proprietary eFlow mesh nebulizer technology. It operates as a contract development and manufacturing organization (CDMO) for respiratory therapeutics, offering end-to-end support from device customization to regulatory strategy and commercial supply. With over 20 years of experience in mesh nebulization, PARI supports a robust pipeline of partner programs, including several in late-stage clinical trials, targeting complex respiratory diseases like non-CF bronchiectasis, pulmonary fibrosis, and bronchiolitis obliterans syndrome.
View full company profileTherapeutic Areas
Other Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Molgramostim (MOLBREEVI) | Savara Pharmaceuticals | Phase 3 |